M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV-1 Research

Executive Summary: M344 is a cell-permeable histone deacetylase (HDAC) inhibitor with a measured IC50 of 100 nM, enabling robust inhibition of HDAC activity in vitro and in vivo (Brumfield et al., 2025). It induces histone acetylation, gene expression modulation, cell differentiation, and apoptosis across multiple cancer cell lines, including neuroblastoma and breast cancer. M344 shows efficacy in overcoming chemoresistance and enhances the response to radiotherapy. It is soluble in DMSO and ethanol, but insoluble in water, requiring specific handling for research applications. APExBIO supplies M344 (SKU A4105) for research use only (APExBIO).

Biological Rationale

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histone tails, resulting in chromatin condensation and transcriptional repression. In cancer and viral latency, aberrant HDAC activity silences genes involved in cell cycle arrest, apoptosis, and immune response (Brumfield et al., 2025). HDAC inhibitors, such as M344, restore histone acetylation, reactivate silenced genes, and modulate the cellular phenotype. M344 has been shown to significantly increase global histone acetylation in neuroblastoma models, leading to downregulation of oncogenic pathways and induction of differentiation. This forms the basis for its application in cancer research and in strategies aiming to reverse HIV-1 latency by reactivating latent proviral genomes (M344: Potent HDAC Inhibitor for Cancer and HIV-1 Research). Unlike broad-spectrum cytotoxics, HDAC inhibitors like M344 can selectively modulate epigenetic states, providing a targeted approach to disease modification.

Mechanism of Action of M344

M344 is a small molecule HDAC inhibitor characterized by its nanomolar potency (IC50 = 100 nM) against HDAC enzymes. Upon cellular entry, M344 inhibits HDACs, particularly class I and II isoforms, resulting in hyperacetylation of histone proteins. This hyperacetylation relaxes chromatin structure, enabling transcription of genes involved in cell cycle arrest, apoptosis, and differentiation (Brumfield et al., 2025). M344 induces pro-apoptotic factors such as Puma through p53-independent mechanisms and modulates transcription factors like NF-κB. In cancer cells, this leads to G0/G1 cell cycle arrest and caspase-dependent cell death. In HIV-1 models, M344 activates the LTR promoter, facilitating latency reversal. Solubility studies confirm M344 is insoluble in water but readily soluble in ethanol (≥12.88 mg/mL with ultrasonication) and DMSO (≥14.75 mg/mL), which are preferred solvents in biological assays (APExBIO).

Evidence & Benchmarks

• M344 exhibits an HDAC inhibition IC50 of 100 nM in enzymatic assays (APExBIO).
• M344 increases histone acetylation and induces G0/G1 cell cycle arrest in neuroblastoma cell lines (Brumfield et al., 2025, DOI).
• Demonstrates potent anti-proliferative effects in MCF-7 breast cancer, D341 MED medulloblastoma, and CH-LA 90 neuroblastoma cells with GI50 values of 0.63–0.65 μM (APExBIO).
• Enhances radiation sensitivity in human squamous carcinoma lines SCC-35 and SQ-20B (APExBIO).
• In vivo, metronomic dosing of M344 suppresses neuroblastoma tumor growth and extends animal survival (Brumfield et al., 2025, DOI).
• M344 increases expression of pro-apoptotic gene Puma via p53-independent pathways (Brumfield et al., 2025, DOI).
• Activates HIV-1 LTR gene expression, supporting its use in latency reversal protocols (M344: Cancer and HIV-1 Research).

Applications, Limits & Misconceptions

M344 is primarily used in:

• Cell-based assays for HDAC pathway research and epigenetic screening.
• Apoptosis and cell cycle analysis in cancer cell lines.
• Studying mechanisms of drug resistance and radiosensitization.
• HIV-1 latency reversal and transcriptional reactivation models.
• Combination therapy research in preclinical oncology.

This article extends previous guides (e.g., Enhancing Cell-Based Assays with M344 (SKU A4105)) by providing updated, quantitative evidence and clarifying solvent compatibility and workflow parameters for reproducibility.

For a broader protocol-driven view, see M344: HDAC Inhibitor for Precision Epigenetic Control, which addresses nuanced experimental endpoints. This article, in contrast, emphasizes peer-reviewed benchmarks and clarifies specific limits of M344 utility.

Common Pitfalls or Misconceptions

• Water solubility: M344 is insoluble in aqueous buffers; use DMSO or ethanol for stock solutions (APExBIO).
• Long-term solution storage: Stock solutions are not stable for extended periods; prepare fresh for each experiment.
• Over-generalization: M344 is not universally effective across all cancer types—efficacy must be empirically validated per model.
• Clinical use: M344 is supplied for research use only and is not approved for diagnostic or therapeutic purposes.
• Concentration limits: Effects outside 1–100 μM or durations beyond 7 days are poorly characterized and not recommended.

Workflow Integration & Parameters

M344 (SKU A4105) is delivered as a solid and should be dissolved in DMSO or ethanol to make stock solutions (≥14.75 mg/mL in DMSO; ≥12.88 mg/mL in ethanol with ultrasonication). Stock solutions must be stored at -20°C and are not intended for long-term use. For cell-based assays, experimental concentrations typically range from 1 μM to 100 μM, with treatment durations of 1–7 days. Assays should include appropriate solvent controls. For apoptosis assays and cell cycle analysis, standard protocols apply with M344 replacing other HDAC inhibitors at equivalent molarity. Researchers can consult this protocol guide for stepwise integration; the present article updates these recommendations with new benchmark data and stability notes.

Conclusion & Outlook

M344 is a potent, cell-permeable HDAC inhibitor enabling advanced studies in cancer biology and HIV-1 latency reversal. Its nanomolar efficacy, robust activity in diverse cell models, and well-characterized mechanism make it a reference standard for apoptosis, cell differentiation, and epigenetic modulation research. APExBIO supplies M344 for research applications, and recent evidence supports its superior performance over older HDAC inhibitors in several preclinical paradigms (Brumfield et al., 2025). Ongoing studies will clarify its translational potential and further define its optimal application range.